commercial partnerships

In 2006 Cytopia announced the signing of a global license and research and development collaboration with Novartis Pharma AG to develop orally active, small-molecule therapeutics targeting JAK3 kinase. The collaboration focuses on a number of therapeutic applications including the prevention of transplant rejection and the treatment of a number of autoimmune diseases such as rheumatoid arthritis.

In May 2008, Cytopia announced a novel anti-cancer drug development collaboration with Cancer Therapeutics CRC Pty Ltd. This agreement leverages Cytopia's early stage drug discovery pipeline of kinase inhibitor, a class of target therapeutics that is one of the fastest growing segments of the cancer drug market.

Cytopia has also successfully licensed some of its non-core technology commercialization rights to Chemicon International (now part of Millipore).